期刊文献+

加替沙星阴道泡腾栓的药效学研究 被引量:1

Pharmacodynamic Study of Gatifloxacin Vaginal Effervescent Suppository
下载PDF
导出
摘要 目的研究加替沙星阴道泡腾栓(GVES)的药效学。方法用3种常见致病菌感染豚鼠阴道,再用GVES治疗,治疗后评价药效,包括治疗后病原体转阴率和阴道病变治愈率。结果GVES低、中、高剂量(23.5,47.0,94.0mg/kg)阴道给药对金黄色葡萄球菌的转阴率分别为90.0%,100%,100%,对大肠杆菌的转阴率分别为95.0%,100%,100%,对淋球菌的转阴率分别为75.0%,95.0%,100%,总有效率分别为81.14%,88.00%,100%。总有效率与环丙沙星(85.71%)无显著性差异(P>0.05)。结论GVES对豚鼠致病菌阴道感染疗效明显。 Objective To study the pharmacodynamics of gatifloxacin vaginal effervescent suppository (GVES) on the guinea pigs+ Methods To infect on the guinea pig's vagina with 3 kinds of common bacteria. Then the guinea pigs were treated by GVES and evaluated for pharmacodynamics. The pharmacodynamic evaluation included bacterial eradication rates and cure rates after treatment. Results GVES was given to the guinea pig's through vagina by 23.5,47. 0, 94. 0mg/kg. The bacterial eradication rates were 90%, 100%, 100% for staphylococcus aurous; 95%, 100%, 100% for Escherichia coil; 75%, 95%, 100% for gonococcus,respectively. The overall efficacy rates were 81. 14%, 88. 00%,100% for GVES,85, 71% for ciprofloxacin vaginal suppository CVS as control,respectively( P〉0. 05), There was no significant difference. Conclusion GVES has obvious efficacy in the treatment of bacterial vaginal infection in guinea pigs,
出处 《中国药业》 CAS 2006年第8期9-10,共2页 China Pharmaceuticals
关键词 加替沙星 阴道泡腾栓 细菌性阴道感染 药效学研究 gatifloxacin vaginal effervescent suppository bacterial vaginal infection pharmacodynamic study
  • 相关文献

参考文献4

二级参考文献34

  • 1盛惊洲,黄敏文,许军,李家泰.国产洛美沙星的体内抗菌作用研究[J].中国抗生素杂志,1994,19(4):243-247. 被引量:11
  • 2赵铀,汤艳云,陆琳.替硝唑与甲硝唑治疗滴虫性阴道炎的疗效比较[J].新药与临床,1996,15(6):367-368. 被引量:4
  • 3Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutant bacteria : measurement and potential use of the mutant selection window [J ]. J Infect Dis, 2002,185 : 561. 被引量:1
  • 4Schmitz FJ, Fluit A, Brisse S, et al. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolone against European Staohylococcus aureus isolates[J]. FEMS Immunol Med Microbiol , 1999,26:281. 被引量:1
  • 5Drlica K, Schmitz FJ. Therapeutic options in an era of decreasing antimicrobial susceptibility[J ]. J Chemother, 2002,14( Suppl 2) : 5. 被引量:1
  • 6Zhao X, Drlica K. Restricting the selection of antibiotic- resistant mutant bacteria: A general strategy derived from fluoroquinolone studies[J ]. Clin Infect Dis, 2001,33 (Suppl 3 ) : S147. 被引量:1
  • 7Allen GP,Kaatz W, Rybak MJ. Activities of mutant prevention concentration- targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model [J]. Antimicrob Agents Chemother, 2003,47(8) : 2606. 被引量:1
  • 8Zhao X, Xu C,Domagala J, et al. DNA topoisomerase targets of the fluoroquinolone :a strategy for avoiding bacterial resistance [J]. Proc Natl Acad Sci USA, 1997,94 : 13991. 被引量:1
  • 9Dong Y, Xu C, Zhao X, et al. Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth ,survival and resistance. [J ] Antimicrob Agents Chemother,1998,42: 2978. 被引量:1
  • 10Sindelar G, zhao X, Liew A, et al. Mutant prevention concentration (MPC) as a measure of fluoroquinolone potency against mycobacteria [J ]. Antimicrob Agents Chemother, 2000,44 (12):3337. 被引量:1

共引文献12

同被引文献5

  • 1Food and Drug Administration (FDA).Approval of CIPRO(o)XR(Ciprofloxacin extended-release tablets)for uncomplicated Urinary tract infections(acute cystitis)[EB/OL].http://www.fda.gov/cder/foi/appletter/2AXP./214731 tr,pdf,2003. 被引量:1
  • 2Bago P,Vcev A,Tomic M,et al.High eradication rate of H.pylori with moxifloxacin-based treatment:a randomized controlled trial[J].Wien Klin Wochenschr,2007,119(11-12):372-378. 被引量:1
  • 3Wael E,Martin E.Guide to selection of Fluoroquianlones in patients with lower respiratory tmct infections[J].Drug,2005,65(7):949-991. 被引量:1
  • 4涂雪琼,梁少琼,李爱莲.莫西沙星阴道泡腾片的毒理学研究[J].中国药业,2008,17(11):19-20. 被引量:6
  • 5谢柏如,王竹珍.环丙沙星栓治疗细菌性阴道炎306例[J].中国新药与临床杂志,1998,17(2):128-128. 被引量:6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部